Roar BidCo s outstanding public offer for Recipharm AB (publ) - Consent granted to correct error in the Convertible Bond Terms
On 14 December 2020, EQT IX
1
2
( Roar BidCo ), announced a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the Convertible Bonds ) ( Holders of Convertible Bonds ) in Recipharm AB (publ) ( Recipharm or the Company ) to tender all their shares
3 and Convertible Bonds to Roar BidCo (the Offer ). An offer document relating to the Offer was made public on 17 December 2020 (the Offer Document ). The Offer was subsequently increased on 28 January 2021 (the Revised Offer ). A supplement to the Offer Document was registered with the Swedish Financial Supervisory Authority on 1 February 2021 (the Supplement ).
Electrolux Nomination Committee s proposal for election of board members
STOCKHOLM, Feb. 1, 2021 /PRNewswire/
In preparation for the Electrolux Annual General Meeting on March 25, Electrolux Nomination Committee has decided to propose the re-election of all board members except Kai Wärn, who has declined re-election. Staffan Bohman is proposed to be re-elected as Chairman of the Board of Directors, and Petra Hedengran, Henrik Henriksson, Ulla Litzén, Karin Overbeck, Fredrik Person, David Porter and Jonas Samuelson as Board Members.
The Nomination Committee comprises Johan Forssell (Chairman), Investor AB, Carina Silberg, Alecta, Tomas Risbecker, AMF – Försäkring och Fonder, and Marianne Nilsson, Swedbank Robur Funds. The committee also includes Staffan Bohman and Fredrik Persson, chairman and member respectively, of the Electrolux Board.
By Reuters Staff
1 Min Read
STOCKHOLM (Reuters) - Buyout group EQT on Thursday raised its cash offer for contract pharmaceutical maker Recipharm, valuing the Swedish company at 24.9 billion Swedish crowns ($2.97 billion).
EQT raised its bid to 232 crowns per share from the 220 crowns it had offered in December.
“We consider this revised offer to be highly compelling for Recipharm’s shareholders,” EQT partner Erika Henriksson said in a statement.
EQT added that the bid would not be increased further.
Recipharm’s board of directors said in a separate statement they unanimously recommended shareholders and owners of convertible bonds to accept the bid.
Offer document regarding Roar BidCo AB s cash offer to the shareholders and Holders of Convertible Bonds in Recipharm AB (publ) made public: EQT
Tel: + 46 8 506 55 334, email: press@eqtpartners.com
For administrative questions regarding the Offer, please contact your bank or the nominee registered as holder of your shares, or, in respect of the Convertible Bonds, Lucid Issuer Services Limited:
Lucid Issuer Services Limited
Attention: Owen Morris
Email: recipharm@lucid-is.com
The information in this press release was submitted for publication by Roar BidCo (contact details to EQT Press Office above) in accordance with the Takeover Rules. The information was submitted for publication on 17 December 2020 at 11.30 (CET).
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN), Astrazeneca PLC (NYSE:AZN) - Private Equity EQT Offers To Acquire Swedish Pharma Recipharm For $2 1B benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.